Solbec falls foul of continuous disclosure laws
02 August, 2005 by Ruth BeranPerth-based Solbec Pharmaceuticals (ASX:SBP) has paid a AUD$33,000 fine after being issued with an infringement notice by the Australian Securities and Investments Commission (ASIC) for allegedly failing to disclose information to the Australian Stock Exchange (ASX) relating to a drug trial.
Cytopia trials given FDA OK
01 August, 2005 by Graeme O'NeillThe US Food and Drug Administration has approved a clinical trial of Melbourne biopharma Cytopia's (ASX:CYT) promising dual-acting lead anti-cancer molecule CYT997.
First Sunshine Heart device implant recipient dies
29 July, 2005 by Ruth BeranThe first patient to receive Sunshine Heart's (ASX:SHC) C-Pulse heart assist device on May 4, has died from multi-organ failure, 11.5 weeks after the implant.
NASDAQ launches new Health Care Index
29 July, 2005 by Ruth BeranThe NASDAQ stock market has launched a new Health Care Index (NASDAQ:IXHC), a market-value weighted index that contains NASDAQ listed companies classified as health, pharmaceutical or biotechnology.
Rockeby biomed raises $1 million
29 July, 2005 by Ruth BeranSingapore's Rockeby biomed (ASX:RBY) has raised just over AUD$1 million in a non-renounceable one-for-one share rights issue to shareholders, approximately $786,000 less than the AUD$1.78 million it hoped for.
ChemGenex receives two ARC linkage grants
28 July, 2005 by Ruth BeranMelbourne and California-based ChemGenex Pharmaceuticals (ASX:CXS) has been awarded two linkage project grants worth AUD$525,000 in cash from the Australian Research Council (ARC) over the next three years.
EQiTX increases equity in ZingoTX
28 July, 2005 by Ruth BeranMelbourne-based biotech managed investment group EQiTX (ASX:EQX) has increased its ownership in pain management company ZingoTX to 54 per cent with an equity instalment of AUD$300,000, bringing its total investment in ZingoTX to $1.9 million.
EvoGenix raises $9 million in oversubscribed IPO
28 July, 2005 by Ruth BeranAntibody therapeutic developer EvoGenix closed its initial public offer (IPO) today oversubscribed, raising AUD$9 million through the issue of 36 million shares at $0.25.
New Chemeq CEO promises 'fresh eyes'
27 July, 2005 by Ruth BeranDavid Williams, the CEO designate of Perth-based antimicrobial specialist Chemeq (ASX:CMQ), begins his new role on August 1 and is excited about running the company.
Biota files claim of up to $430m against GSK
27 July, 2005 by Ruth BeranMelbourne-based biopharma Biota Holdings (ASX:BTA) today took the next step in its lawsuit against GlaxoSmithKline (GSK), filing particulars of loss and damage with the Victorian Supreme Court estimated to be in the range of AUD$308 million to $430 million.
Amrad lands US asthma patent
26 July, 2005 by Graeme O'NeillThe US Patent Office has granted Melbourne biopharma Amrad (ASX:AML) a patent on therapeutic antibodies that recognise for a sub-unit of the interleukin-13 (IL-13) receptor implicated in asthma.
UQ spin-off secures $3.25m for pain therapy
26 July, 2005 by Ruth BeranSpinifex Pharmaceuticals, a drug development company spun out of the University of Queensland, has received a AUD$3.25 million investment commitment to develop therapeutics for the treatment of neuropathic pain.
Chemeq names new CEO
26 July, 2005 by Ruth BeranAntimicrobial specialist Chemeq (ASX:CMQ) has named David Williams its new CEO and director, commencing August 1. Williams was formerly CEO of Epic Energy, a gas transmission company.
First C3 CellSpray XP patient treated
26 July, 2005 by Ruth BeranThe first patient has been treated with Clinical Cell Culture's (C3, ASX:CCE) CellSpray XP at Dortmund Hospital in Germany.
Avexa starts phase IIb trial of HIV drug
25 July, 2005 by Ruth BeranMelbourne-based biotech Avexa (ASX:AVX) has started the phase IIb trial of AVX754, the HIV compound it in-licensed from UK company Shire Pharmaceuticals in January.
